Use of real-world evidence in cancer drug funding decisions in Canada : a qualitative study of stakeholders' perspectives
Copyright 2020, Joule Inc. or its licensors..
BACKGROUND: Real-world evidence (RWE) can provide postmarket data to inform whether funded cancer drugs yield expected outcomes and value for money, but it is unclear how to incorporate RWE into Canadian cancer drug funding decisions. As part of the Canadian Real-World Evidence Value for Cancer Drugs (CanREValue) Collaboration, this study aimed to explore stakeholder perspectives on the current state of RWE in Canada to inform a Canadian framework for use of RWE in cancer drug funding decisions.
METHODS: This was a qualitative descriptive study. Qualitative semistructured interviews were conducted from April to July 2018. Participants were Canadian and international stakeholders who had experience with RWE and drug funding decision-making. Thematic analysis was used to analyze data.
RESULTS: Thirty stakeholders participated in the study. Five themes were identified. Stakeholders indicated that RWE had value in cancer drug funding decisions. However, a cultural shift is needed to adopt RWE in decision-making. Further, the Canadian infrastructure for real-world data is currently inadequate for decision-making, and there is a need for committed investment in building capacity to collect and analyze RWE. Finally, there is a need for increased collaboration among key stakeholders.
INTERPRETATION: The findings of this study suggest that if RWE is to be used in drug funding decisions, there is a need for a cultural shift, improved data infrastructure, committed investment in capacity building and increased stakeholder collaboration. Together with local stakeholder engagement, application of these findings may contribute to optimizing implementation of RWE.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
CMAJ open - 8(2020), 4 vom: 24. Okt., Seite E772-E778 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Clausen, Marc [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 20.05.2021 Date Revised 20.05.2021 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.9778/cmajo.20200118 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318012995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318012995 | ||
| 003 | DE-627 | ||
| 005 | 20231225164453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.9778/cmajo.20200118 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318012995 | ||
| 035 | |a (NLM)33234584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Clausen, Marc |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of real-world evidence in cancer drug funding decisions in Canada |b a qualitative study of stakeholders' perspectives |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2021 | ||
| 500 | |a Date Revised 20.05.2021 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2020, Joule Inc. or its licensors. | ||
| 520 | |a BACKGROUND: Real-world evidence (RWE) can provide postmarket data to inform whether funded cancer drugs yield expected outcomes and value for money, but it is unclear how to incorporate RWE into Canadian cancer drug funding decisions. As part of the Canadian Real-World Evidence Value for Cancer Drugs (CanREValue) Collaboration, this study aimed to explore stakeholder perspectives on the current state of RWE in Canada to inform a Canadian framework for use of RWE in cancer drug funding decisions | ||
| 520 | |a METHODS: This was a qualitative descriptive study. Qualitative semistructured interviews were conducted from April to July 2018. Participants were Canadian and international stakeholders who had experience with RWE and drug funding decision-making. Thematic analysis was used to analyze data | ||
| 520 | |a RESULTS: Thirty stakeholders participated in the study. Five themes were identified. Stakeholders indicated that RWE had value in cancer drug funding decisions. However, a cultural shift is needed to adopt RWE in decision-making. Further, the Canadian infrastructure for real-world data is currently inadequate for decision-making, and there is a need for committed investment in building capacity to collect and analyze RWE. Finally, there is a need for increased collaboration among key stakeholders | ||
| 520 | |a INTERPRETATION: The findings of this study suggest that if RWE is to be used in drug funding decisions, there is a need for a cultural shift, improved data infrastructure, committed investment in capacity building and increased stakeholder collaboration. Together with local stakeholder engagement, application of these findings may contribute to optimizing implementation of RWE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Mighton, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Kiflen, Ruhi |e verfasserin |4 aut | |
| 700 | 1 | |a Sebastian, Agnes |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Wei Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Mercer, Rebecca E |e verfasserin |4 aut | |
| 700 | 1 | |a Beca, Jaclyn M |e verfasserin |4 aut | |
| 700 | 1 | |a Isaranuwatchai, Wanrudee |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Kelvin K W |e verfasserin |4 aut | |
| 700 | 1 | |a Bombard, Yvonne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CMAJ open |d 2013 |g 8(2020), 4 vom: 24. Okt., Seite E772-E778 |w (DE-627)NLM240557662 |x 2291-0026 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |g number:4 |g day:24 |g month:10 |g pages:E772-E778 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.9778/cmajo.20200118 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 |e 4 |b 24 |c 10 |h E772-E778 | ||